☆ 4.6 Article

Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

GYNECOLOGIC ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

GYNECOLOGIC ONCOLOGY
Volume 162, Issue -, Pages S24-S25

Publisher

Elsevier BV
DOI: 10.1016/s0090-8258(21)00693-4

Keywords

-

Categories

Obstetrics & Gynecology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.